Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study.
buprenorphine
cannabidiol
cue-induced craving
opioid use disorder
Journal
Integrative medicine reports
ISSN: 2768-3222
Titre abrégé: Integr Med Rep
Pays: United States
ID NLM: 9918402367706676
Informations de publication
Date de publication:
01 Aug 2022
01 Aug 2022
Historique:
accepted:
28
07
2022
entrez:
15
9
2022
pubmed:
16
9
2022
medline:
16
9
2022
Statut:
ppublish
Résumé
Opioid use disorder (OUD) remains a major public health concern. Despite the use of medications for OUD such as buprenorphine, the current gold-standard treatment, relapse in the context of increased craving remains common. Cannabidiol (CBD) has been shown to reduce cue-induced craving in individuals with OUD, but among those who were not receiving any buprenorphine treatment. This small proof-of-concept open-label study sought to evaluate the effect of CBD on cue-induced craving among individuals with OUD who were being actively treated with buprenorphine. Participants ( All participants were actively taking buprenorphine for an average of 37.8 months (range 1-120 months). Cue-induced craving was significantly lower after CBD dosing compared with baseline (0.4 vs. 3.2, paired Given the high risk for bias in a small uncontrolled open label study such as this, results must be interpreted with caution. A larger adequately powered trial with a suitable control group is needed to confirm the finding that CBD may help to reduce cue-induced craving among individuals with OUD currently on buprenorphine treatment. Research should further evaluate whether adjunctive use of CBD can improve clinical outcomes for individuals with OUD maintained on buprenorphine. ClinicalTrials.gov (NCT04192370).
Sections du résumé
Background
UNASSIGNED
Opioid use disorder (OUD) remains a major public health concern. Despite the use of medications for OUD such as buprenorphine, the current gold-standard treatment, relapse in the context of increased craving remains common. Cannabidiol (CBD) has been shown to reduce cue-induced craving in individuals with OUD, but among those who were not receiving any buprenorphine treatment. This small proof-of-concept open-label study sought to evaluate the effect of CBD on cue-induced craving among individuals with OUD who were being actively treated with buprenorphine.
Methods
UNASSIGNED
Participants (
Results
UNASSIGNED
All participants were actively taking buprenorphine for an average of 37.8 months (range 1-120 months). Cue-induced craving was significantly lower after CBD dosing compared with baseline (0.4 vs. 3.2, paired
Conclusions
UNASSIGNED
Given the high risk for bias in a small uncontrolled open label study such as this, results must be interpreted with caution. A larger adequately powered trial with a suitable control group is needed to confirm the finding that CBD may help to reduce cue-induced craving among individuals with OUD currently on buprenorphine treatment. Research should further evaluate whether adjunctive use of CBD can improve clinical outcomes for individuals with OUD maintained on buprenorphine. ClinicalTrials.gov (NCT04192370).
Identifiants
pubmed: 36105269
doi: 10.1089/imr.2022.0070
pii: 10.1089/imr.2022.0070
pmc: PMC9462449
doi:
Banques de données
ClinicalTrials.gov
['NCT04192370']
Types de publication
Journal Article
Langues
eng
Pagination
157-163Informations de copyright
© Joji Suzuki et al., 2022; Published by Mary Ann Liebert, Inc.
Déclaration de conflit d'intérêts
Dr. Weiss has consulted to Analgesic Solutions, Wayland, MA, ACI Clinical, Bala Cynwyd, PA, and Alkermes, Inc., Waltham, MA. All other authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.
Références
Psychiatry Res. 2022 Feb;308:114347
pubmed: 34952255
J Pers Soc Psychol. 1988 Jun;54(6):1063-70
pubmed: 3397865
Neurotoxicology. 2019 Sep;74:282-298
pubmed: 31412258
Addiction. 2018 May 1;:
pubmed: 29714034
Psychiatr Serv. 2014 Feb 1;65(2):146-57
pubmed: 24248468
Biol Psychiatry. 2011 Oct 15;70(8):720-727
pubmed: 21741031
Am J Addict. 2014 Sep-Oct;23(5):453-8
pubmed: 24628912
Am J Psychiatry. 2017 Aug 1;174(8):738-747
pubmed: 27978771
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Neuropsychopharmacology. 2010 Aug;35(9):1879-85
pubmed: 20428110
Lancet Psychiatry. 2020 Oct;7(10):865-874
pubmed: 32735782
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Neurotherapeutics. 2015 Oct;12(4):807-15
pubmed: 26269227
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Front Pharmacol. 2021 Jan 21;11:618184
pubmed: 33551817
J Addict Med. 2021 Apr 1;15(2):91-92
pubmed: 32909980
Neuropsychopharmacology. 2018 Mar;43(4):859-867
pubmed: 29105663
Drug Alcohol Depend. 2014 Dec 1;145:121-6
pubmed: 25454409
Curr Pain Headache Rep. 2020 Jan 24;24(2):4
pubmed: 31980957
J Psychoactive Drugs. 2003 Apr-Jun;35(2):253-9
pubmed: 12924748
Front Psychiatry. 2019 Feb 19;10:63
pubmed: 30837904
MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):202-207
pubmed: 33571180
Am J Drug Alcohol Abuse. 2018;44(5):502-511
pubmed: 29634425
Br J Pharmacol. 2015 Oct;172(20):4790-805
pubmed: 26218440
Lancet. 2019 Feb 23;393(10173):778-790
pubmed: 30792007
J Clin Med. 2019 Jul 19;8(7):
pubmed: 31330972
Ann Acad Med Singap. 1994 Mar;23(2):129-38
pubmed: 8080219
Drug Alcohol Depend. 2021 Aug 1;225:108764
pubmed: 34051547
Addiction. 2004 Apr;99(4):461-71
pubmed: 15049746
Am J Psychiatry. 2019 Nov 1;176(11):911-922
pubmed: 31109198
Br J Pharmacol. 2015 Feb;172(3):737-53
pubmed: 25257544
Contemp Clin Trials. 2010 Mar;31(2):189-99
pubmed: 20116457
J Neurosci. 2009 Nov 25;29(47):14764-9
pubmed: 19940171
Int J Mol Sci. 2020 Nov 23;21(22):
pubmed: 33238607
Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207
pubmed: 24500948
CMAJ Open. 2019 Nov 19;7(4):E665-E673
pubmed: 31744904
J Clin Med Res. 2020 Mar;12(3):129-141
pubmed: 32231748
Am J Addict. 2016 Mar;25(2):105-9
pubmed: 26848719
Drug Alcohol Depend. 2008 Sep 1;97(1-2):1-20
pubmed: 18479844
Drug Alcohol Depend. 2021 Aug 1;225:108755
pubmed: 34052686
Addict Behav. 2019 Nov;98:106010
pubmed: 31238237